ACE2 as a Target for Hydroxychloroquine/Chloroquine in COVID-19 Treatment
Five potential binding sites between HCQ/CQ and ACE2 were identified using computerized molecular docking assays. Reported values are calculated Glide Standard Precision (SP) Glide Extra Precision (XP) measurements which quantify protein/ligand interactions. These findings support the observation that HCQ is a more effective anti-SARS-CoV-2 drug than CQ in vitro because of HCQ's stronger interaction with the ACE2 allosteric site, which is involved with regulation of the receptor.
0
1
Tags
SARS-CoV-2 (COVID-19)
Biomedical Sciences
Related
ACE2 as a Target for Hydroxychloroquine/Chloroquine in COVID-19 Treatment
ACE 2 Receptor as a Pharmacological Target for Treating or Preventing COVID-19
Other CoVs that Utilize the Human ACE2 Receptor for Entry
SARS-CoV-2 S Protein Conformation and ACE2 Receptor Interaction
ACE2 Interaction with SARS-CoV-2 S Protein by Subunit
SARS-CoV-2 S Protein May Interact with Human Cells Independently of ACE2
ACE2 as a Target for Hydroxychloroquine/Chloroquine in COVID-19 Treatment
ACE2 variants and COVID-19
ADAM17 Induced ACE2 Upregulation May Contribute to SARS-CoV-2 Infections